----

----

**SECURITIES      AND EXCHANGE COMMISSION**

**WASHINGTON,      D.C. 20549**

**FORM      S-8**

**REGISTRATION      STATEMENT UNDER**

**THE      SECURITIES ACT OF 1933**

**PROGENICS      PHARMACEUTICALS, INC.**

**(Exact      name of registrant as specified in its charter)**

| **DELAWARE****(State                or other jurisdiction of incorporation or                organization)** | **777                Old Saw Mill River Road****Tarrytown,                New York 10591****(Address                of Principal Executive Offices) (Zip Code)** | **13-3379479****(I.R.S.                Employer****Identification                No.)** |
|--------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|

**Amended      1998 Employee Stock Purchase Plan **

**Amended      1998 Non-Qualified Employee Stock Purchase Plan**

**(Full      Title of the Plan)**

**Paul      J. Maddon, M.D., Ph.D.**

**Chief      Executive Officer and Chief Science Officer**

**Progenics      Pharmaceuticals, Inc.**

**777      Saw Mill River Road**

**Tarrytown,      New York 10591**

**Telephone      number, including area code, of agent for service: **

**(914)      789-2800**

**CALCULATION      OF REGISTRATION FEE**

| **Title                  of Each Class of****Securities****To                  Be Registered** | **Amount****To                  Be Registered(1)(2)** | **Proposed                  Maximum****Offering                  Price****Per                  Share(3)** | **Proposed                  Maximum****Aggregate                  Offering****Price(3)** | **Amount                  of****Registration                  Fee** |
|------------------------------------------------------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|---------------------------------------------------------------------|
| Common                  Stock, $0.0013 par value per share                                     | 800,000                                               | $22.06                                                                                                    | $17,648,000                                                                              | $541.79                                                             |

| (1) | Represents                600,000 shares issuable upon exercise of options to be granted pursuant                to                the Amended 1998 Employee Stock Purchase Plan and 200,000 shares                issuable                upon exercise of options to be granted pursuant to the Amended 1998                Non-Qualified Employee Stock Purchase                Plan. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (2) | Plus                such additional shares as may be issued by reason of stock splits,                stock                dividends or similar transactions.                                                                                                                                                                                                                                       |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (3) | Pursuant                to Rules 457(h) and 457(c), these prices are estimated solely for                the                purpose of calculating the registration fee and are based upon the                average                of the high and low sales prices of the Registrant's common stock                on the                Nasdaq National Market on June 8, 2007                . |

----

----

----

**EXPLANATORY      STATEMENT**

**PART      I **

**INFORMATION      REQUIRED IN THE SECTION 10(a) PROSPECTUS **

**PART      II**

**INFORMATION      REQUIRED IN THE REGISTRATION STATEMENT**

**Item      3. Incorporation of Documents by Reference.**

|   | a) | The                Registrant's Annual Report on Form 10-K for the fiscal year ended                December                31, 2006 filed with the SEC on March 15,                2007; |
|--------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | b) | The                Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31,                2007 filed with the SEC on May 9, 2007; |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | c) | The                Registrant’s Current Report on Form 8-K filed on January 8, 2007;                and |
|--------|----|---------------------------------------------------------------------------------------------------------------|

|   | d) | The                description of the Company's Common Stock in the Registrant's registration                statement on Form 8-A dated September 29, 1997, File No. 0-23143                pursuant                to Section 12 of the Securities Exchange Act of 1934, as amended                (the                “Exchange Act”) including all amendments or reports filed with the                Commission for the purpose of updating such                description. |
|--------|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**Item      4. Description of Securities.**

**Item      5. Interests of Named Experts and Counsel.**

**Item      6. Indemnification of Directors and Officers.**

----

**Item      7. Exemption from Registration Claimed.**

**Item      8. Exhibits.**

| **Exhibit****Number** |   |   | **Description**                                                                                                                                                                                                                                |   |   |                                                                                                                                                                           |   |
|-----------------------|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| 3.1                   |   |   |  Restated                Certificate of Incorporation of the Registrant                                                                                                                                                                   |   |   | Incorporated                by reference to the Registrant’s Current Report on Form 8-K filed with the                Securities and Exchange Commission on May 13, 2005 |   |
|                  |   |   |                                                                                                                                                                                                                                           |   |   |                                                                                                                                                                           |   |
| 4.1                   |   |   | Specimen                Certificate of Common Stock, $.0013 par value per share, of the                Registrant                                                                                                                              |   |   | Incorporated                by reference to the Registrant’s registration statement on Form S-1, File                no. 333-13627                                       |   |
|                  |   |   |                                                                                                                                                                                                                                           |   |   |                                                                                                                                                                           |   |
| 5.1                   |   |   | Opinion                and Consent of Mark R. Baker, Senior Vice President and General Counsel                of                Progenics Pharmaceuticals, Inc. with respect to the legality of the                securities being registered |   |   | Filed                herewith                                                                                                                                                  |   |
|                  |   |   |                                                                                                                                                                                                                                           |   |   |                                                                                                                                                                           |   |
| 10.1                  |   |   | Amended                1998 Employee Stock Purchase Plan                                                                                                                                                                                       |   |   | Filed                herewith                                                                                                                                                  |   |
|                  |   |   |                                                                                                                                                                                                                                           |   |   |                                                                                                                                                                           |   |
| 10.2                  |   |   | Amended                1998 Non-Qualified Employee Stock Purchase Plan                                                                                                                                                                         |   |   | Filed                herewith                                                                                                                                                  |   |
|                  |   |   |                                                                                                                                                                                                                                           |   |   |                                                                                                                                                                           |   |
| 23.1                  |   |   | Consent                of Mark R. Baker, Senior Vice President and General Counsel, Progenics                Pharmaceuticals, Inc. (contained in his opinion filed herewith as                Exhibit                5.1)                      |   |   | Filed                herewith                                                                                                                                                  |   |

----

|   |   |   |                                                                                                                                         |   |   |                          |   |
|--------|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|-------------------------------|--------|
| 23.2   |   |   | Consent                of PricewaterhouseCoopers LLP                                                                                         |   |   | Filed                herewith |   |
|   |   |   |                                                                                                                                         |   |   |                          |   |
| 24.1   |   |   | Power                of Attorney of directors and certain officers of the Company (included                in                Signature Page) |   |   | Filed                herewith |   |

**Item      9. Undertakings.**

(2)      That,      for the purpose of determining any liability under the Securities Act of 1933,      each such post-effective amendment shall be deemed to be a new registration      statement relating to the securities offered therein, and the offering of such      securities at that time shall be deemed to be the initial bona fide offering      thereof.

----

**SIGNATURES**

*The      Registrant*

|   |   | PROGENICS                PHARMACEUTICALS, INC. |
|--------|--------|------------------------------------------------|

|   | By:    | /s/                PAUL J. MADDON, M.D., PH.D.                                  |
|--------|--------|---------------------------------------------------------------------------------|
|   |   | Paul                J. Maddon, M.D., Ph.D.                                      |
|   |   | Chief                Executive Officer and Chief Science                Officer |

----

**POWER      OF ATTORNEY**

| **Signature**                                                                                      | **Capacity**                                                                                                                                                      |   | **Date**                     |
|----------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------------------------|
|                                                                                               |                                                                                                                                                              |   |                         |
| /s/                KURT W. BRINERKurt                W. Briner                                     | Co-Chairman                of the Board                                                                                                                           |   | June                12, 2007 |
|                                                                                               |                                                                                                                                                              |   |                         |
| /s/                PAUL F. JACOBSONPaul                F. Jacobson                                 | Co-Chairman                of the Board                                                                                                                           |   | June                12, 2007 |
|                                                                                               |                                                                                                                                                              |   |                         |
| /s/                PAUL J. MADDON, M.D., PH.D.Paul                J. Maddon, M.D., Ph.D.           | Chief                Executive Officer and Chief Science Officer (Principal Executive                Officer)                                                     |   | June                12, 2007 |
|                                                                                               |                                                                                                                                                              |   |                         |
| /s/                ROBERT A. MCKINNEYRobert                A. McKinney                             | Chief                Financial Officer, Senior Vice President, Finance & Operations and                Treasurer (Principal Financial and Accounting Officer) |   | June                12, 2007 |
|                                                                                               |                                                                                                                                                              |   |                         |
| /s/                CHARLES A. BAKERCharles                A. Baker                                 | Director                                                                                                                                                          |   | June                12, 2007 |
|                                                                                               |                                                                                                                                                              |   |                         |
| /s/                MARK F. DALTONMark                F. Dalton                                     | Director                                                                                                                                                          |   | June                12, 2007 |
|                                                                                               |                                                                                                                                                              |   |                         |
| /s/                STEPHEN P. GOFF, Ph.D.Stephen                P. Goff, Ph.D.                     | Director                                                                                                                                                          |   | June                12, 2007 |
|                                                                                               |                                                                                                                                                              |   |                         |
| /s/                DAVID A. SCHEINBERG, M.D., PH.D.David                A. Scheinberg, M.D., Ph.D. | Director                                                                                                                                                          |   | June                12, 2007 |
|                                                                                               |                                                                                                                                                              |   |                         |
| /s/                NICOLE S. WILLIAMS                                                              | Director                                                                                                                                                          |   | June                12, 2007 |
| Nicole                S. Williams                                                                  |                                                                                                                                                              |   |                         |